Stimulates insulin release from the pancreatic beta cells; reduces glucose output from the liver; insulin sensitivity is increased at peripheral target sites
Glimepiride Interactions
Pretreatment with rifampicin moderately decreased plasma glimepiride concentrations (Figure 1 and Table 2)
Hyounggyoon Yoo
Glimepiride is one of the most widely prescribed antidiabetic drugs and contains both hydrophobic and hydrophilic functional groups in its molecules, and thus
1, January 2023, pp
glimepiride levels, risk of hypoglycemia, other adverse effects (hepatic metab
The effects of glimepiride on HbA 1c, fasting plasma glucose, and postprandial glucose have been assessed in clinical trials [see Clinical Studies ]
Possible pharmacodynamic and pharmacokinetic interactions were observed for, following single-dose as well as multiple-dose treatment protocols in normal and alloxan-induced diabetes in albino Wistar rats and rabbits
4 ng/mL and 1 hour
Possible pharmacodynamic and pharmacokinetic interactions were observed for, following single-dose as well as multiple-dose treatment protocols in normal and alloxan-induced diabetes in albino Wistar rats and rabbits
Comparison of glimepiride pharmacokinetics in Type 2 diabetic patients ≤65 years and those >65 years was performed in a study using a dosing regimen of 6 mg daily
There Aims: To study the effects of rifampicin on the pharmacokinetics and pharmaco-dynamics of glimepiride, a new sulphonylurea antidiabetic drug
Further it is also aimed